NCT06915701RecruitingPhase 2/3
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
"Evaluation of the Effect of Vitamin E (α-tocopherol) Supplementation on Clinical Activity and Inflammation in Patients With Rheumatoid Arthritis"
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are: * Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA? Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis. Participants will: * Take two capsules (one in the morning and one in the afternoon) of either α-tocopherol or placebo every day for a month. * Attend clinic visits at the start of the intervention (baseline) and at the end of the month for final check-ups and tests. * Keep a diary to record your symptoms and how often you take α-tocopherol or placebo.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 4 Nov 2024
- Start date
- 6 Feb 2026
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- University of Guadalajara
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT06915701
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 46
- From 6 Feb 2026 to the primary completion date, 15 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Consumption of supplements (iron, vitamin E, and K), and medications such as acetylsalicylic acid, amlodipine, estrogen, glucocorticoids and drugs used to treat dyslipidemias in the last three months.
- Elimination Criteria:
Other illness
- Liver and kidney disease
- Overlap syndrome
- Coagulation disorders
Other
- Pregnancy
- Errors in administration of the 20% supplement
- Adverse effects of the supplement
- Pregnancy during the study
- Insufficient blood sample
- Voluntary withdrawal of informed consent.
Who the study is looking for
- Female sex
- RA classification (ACR/EULAR 2010)
- Early RA 2 years
- Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations)
- DAS28 ≥3.2
- Vitamin E intake deficiency (\<15mg/day)
- No comorbidities
- Age \> 18 years
- Voluntary participation and informed consent.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universidad de Guadalajara Coordinator of this site? Confirm its status | Guadalajara | Mexico | Not yet recruiting |
| Civil Hospital of Guadalajara Coordinator of this site? Confirm its status | Guadalajara | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.